Last reviewed · How we verify
PM060184
At a glance
| Generic name | PM060184 |
|---|---|
| Sponsor | PharmaMar |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors (PHASE1)
- Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment (PHASE2)
- Study of PM060184 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PM060184 CI brief — competitive landscape report
- PM060184 updates RSS · CI watch RSS
- PharmaMar portfolio CI